Condor Capital Management’s Phoenix Biotech Acquisition Corp. Unit PBAXU Stock Holding History

Condor Capital Management’s Portfolio PBAXU Stock Details PBAXU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-5,380	Closed	-$54K	–	327
2022 Q3	$54K	Hold	5,380	–	–	0.01%	282
2022 Q2	$54K	Sell	5,380 -1,000	-16%	-$10.1K	0.01%	270
2022 Q1	$64K	Hold	6,380	–	–	0.01%	250
2021 Q4	$64K	Buy	+6,380	New	+$64.6K	0.01%	223

Other funds holding PBAXU

YCM

Yakira Capital Management Westport, Connecticut $351M AUM 21.82% 1-Year Est. Return

FTUS

Flow Traders U.S. New York $2.43B AUM 44.44% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Condor Capital Management's PBAXU Position: Q4 2022 in Review

Condor Capital Management sold out of Phoenix Biotech Acquisition Corp. Unit (PBAXU) in Q4 2022, closing a stake of 5,380 shares — an estimated $54K sold.

Condor Capital Management first reported a position in PBAXU in Q4 2021 and held it in 4 quarters. The position peaked at $64K in Q1 2022. 3 funds tracked by Wall St. Rank hold PBAXU as of Q4 2022.

Condor Capital Management reported no remaining Phoenix Biotech Acquisition Corp. Unit position as of Q4 2022 after selling out during the quarter.
Condor Capital Management sold 5,380 Phoenix Biotech Acquisition Corp. Unit shares in Q4 2022, an estimated $54K.
Condor Capital Management first reported a position in Phoenix Biotech Acquisition Corp. Unit in Q4 2021 and held it in 4 quarters.
Condor Capital Management's Phoenix Biotech Acquisition Corp. Unit position peaked at $64K in Q1 2022.
3 funds tracked by Wall St. Rank held Phoenix Biotech Acquisition Corp. Unit as of Q4 2022.

Based on Condor Capital Management's 13F filing for Q4 2022, filed 7 Feb 2023.